Document is current
Any future updates will be listed below
-
Authors
Jing, Ying
Liu, Jin
Ye, Youqiong https://orcid.org/0000-0001-8332-4710
Pan, Lei
Deng, Hui
Wang, Yushu
Yang, Yang
Diao, Lixia https://orcid.org/0000-0001-6995-4492
Lin, Steven H. https://orcid.org/0000-0003-4411-0634
Mills, Gordon B. https://orcid.org/0000-0002-0144-9614
Zhuang, Guanglei https://orcid.org/0000-0001-8141-5096
Xue, Xinying https://orcid.org/0000-0002-7847-8034
Han, Leng https://orcid.org/0000-0002-7380-2640
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RR150085)
- License Information
-
More Information
Article History
Received: 13 March 2020
Accepted: 8 September 2020
First Online: 2 October 2020
Competing interests
: G.B.M. has sponsored research support from AstraZeneca, Critical Outcomes Technology, Karus, Illumina, Immunomet, Nanostring, Tarveda, and Immunomet, and is on the Scientific Advisory Board for AstraZeneca, Critical Outcomes Technology, ImmunoMet, Ionis, Nuevolution, Symphogen, and Tarveda. The remaining authors declare no competing interests.
